| 摘要 |
The present invention provides novel imidazolidinonyl aminopyrimidine com pounds believed to have clinical use for treatment of cancer through inhibit ing Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di (C1-C2 alkyl)aminomethyl, N- ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C 1-C2 alkyl)amino)-ethyl, 3,3,3- trifluoropropylaminomethyl, ethynyl, 2-hydro xy-ethoxy, 2-hydroxyethylaminomethyl, 2- cyanoethylaminomethyl, mopholin-4-y lmethyl, methoxymethoxymethyl, cyclopropyl, 1- azetidinylmethyl, 1-pyrrolidi nylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or h alo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, me thyl, or halo; and is a single bond that is either present or absent, or a p harmaceutically acceptable salt thereof.
|
